I'll research BG (Bunge Global) before writing the preview. Let me gather recent earnings materials, transcripts, and news.Let me read the most recent earnings materials (2026Q1) and get broader news.Let me get the prior-year Q2 comparison, recent news, and stock price trend.Let me check recent news and analyst context via web search.# Bunge Global (BG) — Q2 2026 Earnings Preview Report date: Wednesday, July 29, 2026 (before market open) | Call: 8:00 a.m. ET | Prior close (7/28): ~$117.40
Bunge enters this report with strong momentum but an interesting expectations gap. On the Q1 call (April 29), management raised full-year 2026 adjusted EPS guidance to $9.00–$9.50, up sharply from $7.50–$8.00 — a rare mid-cycle guide-up of ~$1.50 driven by a soybean/softseed crush and biofuel-demand surge. Q1 adjusted EPS came in at $1.83 vs. $1.81 a year earlier, but adjusted segment EBIT jumped to $661M from $406M, well ahead of the company's own prior expectation (management had guided Q1 to the "low-$0.80s" range on the prior call).
The key tension for tomorrow: Sell-side consensus sits at roughly $2.03 adjusted EPS (+~55% YoY) on ~$23.5B revenue (+~84% YoY) per Zacks/Yahoo compilations. But Bunge's own implied Q2 guidance is meaningfully lower. On the Q1 call, CFO John Neppl framed the year as ~40% H1 / 60% H2, which — against the $9.25 midpoint — implies H1 of ~$3.70 and therefore a Q2 in the ~$1.85–$1.90 range. So the Street is modeling a beat versus the company's cadence, and Bunge has topped consensus in each of the last several quarters. Watch whether the beat comes from operations or simply from conservative internal guidance.
This is the single biggest swing factor for the stock. The Q1 raise was powered by the Middle East/Iran conflict spiking crude and soybean oil, pulling forward biofuel and discretionary-blending economics and triggering heavy global farmer selling on the flat-price rally. Since then, soybeans have pushed to ~$12.4/bu (near the highest since May 2024) on strong Chinese export demand, higher crude, and weather concerns — a supportive backdrop. However, management was explicit that the raise was front-half-weighted and that H2 visibility is limited because forward crush curves are "heavily inverted" and both farmers and end-consumers (food and energy) are reluctant to engage forward. Any H2 guidance change hinges on how those inverted curves resolve.
As of Q1 2026, Bunge reorganized into four reportable segments. Watch each: - Soybean Processing & Refining — the profit engine; Q1 strength was led by South America (Argentina/Brazil) plus North America. Look for continued strong crush and resilient refining premiums (well below 2022–23 peaks but "resilient"), plus strong oilseed merchandising from farmer selling. - Softseed Processing & Refining — broad-based strength (Argentina, N. America, Europe, Canada/Australia canola). A new European sunseed crop is a potential H2 tailwind after two poor crops; watch commentary. - Tropical Oils & Specialty Ingredients — flagged as a relative weak spot. Management guided Q2 tougher on cocoa-butter-equivalent margins (cocoa prices down), palm dynamics, softer food volumes, and tariff uncertainty keeping customers "short bought." - Grain Merchandising & Milling — Q1 was a -$76M reported EBIT / +$44M adjusted disappointment, hit by an ocean-freight/bunker-fuel cost spike. This is the hardest segment to forecast; watch for a rebound and whether feed-grain/wheat balance sheets tighten.
Management pre-warned that Q2 would carry higher interest expense (FY guide raised to $620–660M on higher working capital / commodity prices) and a normalizing tax rate (Q1 was an unusually low ~18%; FY guided 22–26%), plus higher corporate expense on performance-comp timing. This is precisely why the implied Q2 EPS is roughly flat versus Q1 despite better board margins — a nuance to keep in mind when parsing any "miss" versus the higher Street number.
The transformational Viterra combination closed July 2, 2025, so this is the first Q2 that fully reflects the combined company (prior-year Q2 2025 adjusted EPS of $1.31 excluded Viterra — hence the optically huge YoY growth). Management said cost synergies are running ahead of plan, with ~$190M of synergies targeted in 2026, and additional network/commercial opportunities identified. Any upsized synergy target would be a positive catalyst. Integration/acquisition costs continue to flow through as adjustments.
BG is up roughly 27% YTD (from ~$92.64 to ~$117.40). Shares ran to a ~$131 high in early June, then sold off to ~$105 by early July (coinciding with easing crude/geopolitical premium), and have rebounded into the print but remain below the June peak. With the Street modeling above the company's implied guide and momentum names priced for continuation, the reaction will likely hinge less on the Q2 headline and more on (a) whether the full-year guide moves higher again and (b) management's tone on H2 visibility as those inverted curves either firm up or unwind.
Expect a strong headline YoY (first full combined-company Q2, easy $1.31 comp) and a likely beat versus Bunge's conservative internal cadence. The debate is quality and durability: crush/biofuel tailwinds and Viterra synergies are real, but H2 visibility is genuinely limited, tropicals and below-the-line costs are headwinds, and the shares already reflect a lot of good news. The three things to fixate on: any FY guide raise, H2 curve commentary, and buyback/synergy signals.
Note: "consensus," "revenue," and macro commodity figures above are drawn from public sell-side/news compilations (Zacks, Yahoo Finance, Reuters, Fastmarkets) and should be treated as approximate; all Bunge-specific financials and guidance are from the company's Q1 2026 release and earnings call and the Q2 2025 release.